The effect of simultaneous oral administration of vitamin D, zinc, calcium and magnesium on type 2 diabetes
- Conditions
- Diabetes.Type 2 diabetes mellitus
- Registration Number
- IRCT20190402043157N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 78
Adults (18 years of age and under 65 years of age)
People with type 2 diabetes who use the same drug (metformin, glibenclamide, metformin-repaglinide).
Pregnant and lactating people
People who are going to have a pregnancy
Smoking and alcohol
People with polycystic ovary syndrome (if accompanied by type 2 diabetes insulin resistance)
Having any underlying heart disease and cancer
Species that have kidney, liver and chronic diseases or acute inflammation (especially acute pancreatic inflammation) and thyroid gland diseases
Cystic fibrosis (malabsorption)
People with gastrointestinal diseases (celiac disease, Crohn's disease, peptic ulcer, diverticulosis, IBD, IBS)
People undergoing gastric bypass surgery (malabsorption)
People undergoing cholecystectomy (malabsorption)
Specimens that were under hormone therapy
Insulin injections (due to effect on body weight and insulin levels)
Change in the type and dosage of the medications consumed during the intervention
Not taking supplements (vitamin D and calcium, etc.) up to three months before the study
were treated with drugs and weight loss supplements (such as orlistat or dietary supplements)
People who use drugs that cause hyperglycaemia, such as oral or injectable corticosteroids (including prednisone, prednisolone, dexamethasone, triamcinolone, hydrocortisone or betamethasone)
People with diabetic foot ulcer
Change in the level of physical activity and intense physical activity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum insulin serum level (µIU / ml), 5. 10 ± 1.20 in the placebo group and 7.9 ± 2.7 in the intervention group. Timepoint: Measuring blood insulin at the beginning and end of the study. Method of measurement: Insulin ELISA will be measured.
- Secondary Outcome Measures
Name Time Method